- Published: 17 April 2015
- Written by Editor
Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of Neurology's (AAN) 2015 Annual Meeting
CAMBRIDGE, Mass., April 17, 2015 -- Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of two posters comparing gene expression profiles and additional methods used to show equivalence between GlatopaTM and daily COPAXONE(R) 20 mg (glatiramer acetate injection). The posters will be presented at the 67th AAN Annual Meeting taking place April 18 -- 25, 2015 in Washington, D.C.
Poster Presentation Details
Title: Comparative Gene Expression Profiling between a Generic (Glatopa) and Brand COPAXONE (glatiramer acetate injection)
Poster Number: P1.144
Presentation Date/Time: Monday, April 20, 2015; 2:00 p.m. -- 6:30 p.m. EDT
Title: Demonstration of Equivalence between a Generic (Glatopa) and Brand COPAXONE (glatiramer acetate injection)
Poster Number: P1.145
Presentation Date/Time: Monday, April 20, 2015; 2:00 p.m. -- 6:30 p.m. EDT
About GlatopaTM
Once daily Glatopa (glatiramer acetate injection), developed in collaboration with Sandoz, is the first FDA-approved generic version of daily COPAXONE(R) 20 mg for patients with relapsing forms of multiple sclerosis. Produced entirely in the United States, once daily Glatopa has been determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, and is an "AP" rated, fully-substitutable product. As a therapeutically equivalent generic product, once daily Glatopa contains the same active ingredients, route of administration, strength, and dosage form, and can be substituted with the full expectation that Glatopa will produce the same clinical effect and safety profile as daily COPAXONE 20 mg. Daily COPAXONE 20 mg is one of the leading products marketed to treat multiple sclerosis, and is frequently prescribed as a first-line therapy in newly diagnosed patients.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
COPAXONE is a registered trademark of Teva Pharmaceuticals. Glatopa is a trademark of Novartis AG.
Investor Relations: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 This email address is being protected from spambots. You need JavaScript enabled to view it. Media Relations: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060 This email address is being protected from spambots. You need JavaScript enabled to view it.
